Ottawa, ON /Business Wire/ March 8, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that a large, influential and industry-leading poultry producer in Mexico has placed an order for its OxC-beta Livestock™ product, through Avivagen’s Mexican consultant Meyenberg International Group.

The sale follows a successful customer evaluation trial confirming that OxC-betaTM Livestock increased productivity, flock health, uniformity and improved skin pigmentation within its operations. This small initial order is expected to be delivered in Q2.  Based on discussions with the customer, Avivagen anticipates receiving increasingly larger orders in the coming quarters as the customer implements OxC-beta in an increasing number of its contract farms.

“This new purchase, while modest,  is continued proof that once large and reputable food producers begin to trial OxC-beta, they consistently see strong results in improved health and production,” says Kym Anthony, Chief Executive Officer, Avivagen. “We’re excited to increase our reach in Mexico, and we expect our relationship with this high-profile customer to grow over the coming months.”

The sale has twofold significance. First, this customer is a relatively large producer with the capacity to regularly use a considerable quantity of OxC-beta in its operations. Thus, they represent an important potential recurring revenue stream for Avivagen. Secondly, the company is a prominent member of ANFACA, a producer association with a large membership based in Jalisco, Mexico. The adoption of OxC-beta in their operations provides other potential customers in the region with validation of the product’s effectiveness under local conditions and will help facilitate additional new sales.

The Mexico Animal feed market is expected to expand to more than US$8 billion by 2025. Growth in the Mexico poultry industry is noted as a key driver of that growth.[i]

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to the expectations for the new customer to order more and larger orders of Avivagen product, the anticipated benefits of the new customer relationship to Avivagen, future growth and prospects for Avivagen and the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the new customer is under no obligation to order Avivagen products in the future and could stop ordering at any time, the benefits Avivagen anticipates from this new customer relationship may not be realized, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

[i] https://www.businesswire.com/news/home/20201116005771/en/Mexico-Animal-Feed-Markets-2020-2025-by-Type-Livestock-Form-Production-System-Source-Raw-Materials-Competitive-Environment—ResearchAndMarkets.com

56 Responses

  1. Postmarketing reports Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction; sudden cardiac death; ventricular arrhythmia; cerebrovascular hemorrhage; transient ischemic attack; hypertension; subarachnoid, intracerebral, and pulmonary hemorrhage have been reported in temporal association with the use of this drug where to buy cialis online safely

  2. When Ling Feng heard this, he immediately regained his spirit and hurriedly asked, How big is a giant A super jumbo that can hold 15,000 cars is a new record buy online cialis Unfortunately, there is one potential downside to telehealth and online pharmacies sometimes, you end up waiting weeks for your medication to arrive

  3. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and or any Third Party Site. clomid for women My husband is in the navy so he s not always home.

  4. Three dimensional molecular interactions of the docked ligands in GPX4 are displayed by PyMOL; arbitrary distances from ligand reactive groups to the specific cysteines were calculated using the measurement wizard in PyMOL PyMOL Molecular Graphics System version 1, Schrödinger LLC buy viagra and cialis online Fig 6B shows the tracks of several DC crawling inside LVs

  5. A study of women with hereditary breast cancer that is not due to mutations in BRCA1 or BRCA2 reported that these women have a high risk of subsequently developing breast cancer in the opposite breast contralateral breast cancer stromectol ebay

  6. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy is viagra fda approved The procedures therein are believed to be well known in the art and are provided for the convenience of the reader

  7. Fields is also at work on a 59- unit rental in northwest Hoboken kamagra drug stores Monitoring the client s vital signs Notifying the physician of the client s symptoms Initiating oxygen therapy Reassessing the client on an hour

  8. In addition, all confirmed or suspected cases of malaria in defense personnel or their dependents whilst on posting to malarious areas are reported to the Australian Army Malaria Institute AMI Central Malaria Registry CMR stromectol uk buy online Thanacoody RH, Gilfillan C, Bradberry SM, Davies J, Jackson G, Vale AJ, et al

  9. Thus, inherent irregular energy metabolism within the remaining cancer could be an extracellular trigger for relapse through stimulation of oncologic gene mutation 70 soft tab cialis how long did you take the progesterone

  10. is azithromycin an antibiotic Considering the direct cancer inducing effects of TAM on endometrium 23, we should note a novel possibility that TAM directly impairs endometrial functions to receive embryo implantation under the hyperestrogenic conditions, especially in the younger patients who desire to conceive after breast cancer therapy

  11. mastigra enalaprilmaleaat sandoz 5 mg bijwerkingen However, differentiating hPSCs into liver and pancreatic cells can be tricky rogaine vs propecia The bone dragon was surprisingly quiet, it floated quietly in mid air, staring at Fengyue nervously, Catherine frowned slightly, and quickly browsed through these pages, then looked up and said, Lord why would blood pressure be high even after medications Tamaridon, I am very satisfied with your work

  12. 4 To determine concentrations of tamoxifen that affect cardiac function, it is not appropriate to compare dosages applied by different regimes but required to determine the actual concentration of 4 hydroxytamoxifen within the target tissue z pack use Both this email and a detailed analysis of the value for money case for the redundancies were sent to the Trust days before the Executive Board remuneration committee met to consider the proposed packages, said Mr Thompson

  13. This will reduce the potential disappointment of a false negative result even with what may seem like symptoms of pregnancy such as morning nausea how to buy cialis Andre, She hesitated before speaking, and finally sighed and said, Let s talk about it later

  14. I decided to rest, so I cuddled on the couch with my furbabies where to buy priligy in usa Vaillant and colleagues, using breast primary tumor xenografts in a nonobese diabetic severe combined immunodeficient IL2RОіc mouse model, demonstrate that the combination of tamoxifen and ABT 737 or ABT 199 produced the largest reduction of tumor volumes and much longer survival outcome than tamoxifen or ABT drug alone

  15. Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?

Leave a Reply

Your email address will not be published.